Synthesis and preclinical evaluation of [11C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brain
Open Access
- 5 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 48 (10), 3101-3112
- https://doi.org/10.1007/s00259-021-05269-4
Abstract
Purpose Phosphodiesterase (PDE) 7 is a potential therapeutic target for neurological and inflammatory diseases, although in vivo visualization of PDE7 has not been successful. In this study, we aimed to develop [11C]MTP38 as a novel positron emission tomography (PET) ligand for PDE7. Methods [11C]MTP38 was radiosynthesized by 11C-cyanation of a bromo precursor with [11C]HCN. PET scans of rat and rhesus monkey brains and in vitro autoradiography of brain sections derived from these species were conducted with [11C]MTP38. In monkeys, dynamic PET data were analyzed with an arterial input function to calculate the total distribution volume (VT). The non-displaceable binding potential (BPND) in the striatum was also determined by a reference tissue model with cerebellar reference. Finally, striatal occupancy of PDE7 by an inhibitor was calculated in monkeys according to changes in BPND. Results [11C]MTP38 was synthesized with radiochemical purity ≥99.4% and molar activity of 38.6 ± 12.6 GBq/μmol. Autoradiography revealed high radioactivity in the striatum and its reduction by non-radiolabeled ligands, in contrast with unaltered autoradiographic signals in other regions. In vivo PET after radioligand injection to rats and monkeys demonstrated that radioactivity was rapidly distributed to the brain and intensely accumulated in the striatum relative to the cerebellum. Correspondingly, estimated VT values in the monkey striatum and cerebellum were 3.59 and 2.69 mL/cm3, respectively. The cerebellar VT value was unchanged by pretreatment with unlabeled MTP38. Striatal BPND was reduced in a dose-dependent manner after pretreatment with MTP-X, a PDE7 inhibitor. Relationships between PDE7 occupancy by MTP-X and plasma MTP-X concentration could be described by Hill’s sigmoidal function. Conclusion We have provided the first successful preclinical demonstration of in vivo PDE7 imaging with a specific PET radioligand. [11C]MTP38 is a feasible radioligand for evaluating PDE7 in the brain and is currently being applied to a first-in-human PET study.Keywords
Funding Information
- Mitsubishi Tanabe Pharma Corporation
This publication has 25 references indexed in Scilit:
- Amyloid β-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibitionAlzheimer's Research & Therapy, 2018
- Phosphodiesterase 7 Inhibition Induces Dopaminergic Neurogenesis in Hemiparkinsonian RatsStem Cells Translational Medicine, 2015
- Select 3′,5′-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brainCellular Signalling, 2014
- Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)Endocrine Reviews, 2013
- New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disordersExpert Opinion on Drug Discovery, 2013
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissuesNeuropharmacology, 2010
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brainNeuroscience, 2005
- Differential distribution of cAMP‐specific phosphodiesterase 7A mRNA in rat brain and peripheral organsSynapse, 2001